A new target for gene therapy—splicing factor PUF60

Abstract

Abstract:Poly(U) binding splicing factor 60 KDa (PUF60), a U2related splicing factor that facilitates 3′splicesite recognition at the early stage of spliceosome assembly. High expression of PUF60 is related to the occurrence of multiple tumors, such as colorectal cancer, ovarian cancer, gastric cancer, liver cancer, et al. PUF60 can regulate the expression of cmyc through the corehuman transcription factor Ⅱ basal transcription factor. AntiPUF60 antibodies are detected in the sera of patients with earlystage and recurrent tumor, and the levels are significantly decreased after the operation. PUF60 can be used as a combined or independent test index for the diagnosis of cancer, which can be a potential new target for gene therapy.

Key words:Neoplasms,Genes, myc,DNA, recombinant

Zhang Cancan, Zhang Rong. A new target for gene therapy—splicing factor PUF60[J]. Journal of International Oncology, 2017, 44(7): 531-533.

References

［1］ Rahmutulla B, Matsushita K, Satoh M, et al. Alternative splicing of FBPinteracting repressor coordinates cMyc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycininduced DNA damage pathway［J］. Oncotarget, 2014, 5(9): 2404-2417. DOI: 10.18632/oncotarget.1650. ［2］ Ren C, Chen T, Sun H, et al. The first echinoderm polyUbinding factor 60 kDa (PUF60) from sea cucumber (stichopus monotuberculatus): molecular characterization, inducible expression and involvement of apoptosis［J］. Fish Shellfish Immunol, 2015, 47(1): 196-204. DOI: 10.1016/j.fsi.2015.09.001. ［3］ Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy［J］. Oncogene, 2015, 34(1): 1-14. DOI: 10.1038/onc.2013.570. ［4］ Kralovicova J, Knut M, Cross NC, et al. Identification of U2AF(35)dependent exons by RNASeq reveals a link between 3′ splicesite organization and activity of U2AFrelated proteins［J］. Nucleic Acids Res, 2015, 43(7): 3747-3763. DOI: 10.1093/nar/gkv194. ［5］ Matsushita K, Tamura M, Tanaka N, et al. Interactions between SAP155 and FUSEbinding proteininteracting repressor bridges cMyc and P27Kip1 expression［J］. Mol Cancer Res, 2013, 11(7): 689-698. DOI: 10.1158/1541-7786.MCR-12-0673. ［6］ Sveen A, Kilpinen S, Ruusulehto A, et al. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes［J］. Oncogene, 2016, 35(19): 2413-2427. DOI: 10.1038/onc.2015.318. ［7］ Upheber S, Karle A, Miller J, et al. Alternative splicing of KAI1 abrogates its tumorsuppressive effects on integrin αvβ3mediated ovarian cancer biology［J］. Cell Signal, 2015, 27(3): 652-662. DOI: 10.1016/j.cellsig.2014.11.028. ［8］ Choi JW, Lee JW, Kim JK, et al. Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer［J］. J Mol Cell Biol, 2012, 4(3): 164173. DOI: 10.1093/jmcb/mjs018. ［9］ Matsushita K, Tomonaga T, Shimada H, et al. An essential role of alternative splicing of cmyc suppressor FUSEbinding proteininteracting repressor in carcinogenesis［J］. Cancer Res, 2006, 66(3): 1409-1417. DOI: 10.1158/0008-5472.CAN-04-4459. ［10］ Kobayashi S, Hoshino T, Hiwasa T, et al. AntiFIRs (PUF60) autoantibodies are detected in the sera of earlystage colon cancer patients［J］. Oncotarget, 2016, 7(50): 82493-82503. DOI: 10.18632/oncotarget.12696. ［11］ Cheng L, Wang P, Yang S, et al. Identification of genes with a correlation between copy number and expression in gastric cancer［J］. BMC Med Genomics, 2012, 5: 14. DOI: 10.1186/1755-87945-14. ［12］ Huang H, Han Y, Wu J, et al. Establishment of drug resistant cell line of MGC803 and analysis of differential secretome［J］. Beijing Da Xue Xue Bao, 2014, 46(2): 183-189. ［13］ Malz M, Bovet M, Samarin J, et al. Overexpression of far upstream element (FUSE) binding protein (FBP)interacting repressor (FIR) supports growth of hepatocellular carcinoma［J］. Hepatology, 2014, 60(4): 12411250. DOI: 10.1002/hep.27218. ［14］ Ramakrishna M, Williams LH, Boyle SE, et al. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis［J］. PLoS One, 2010, 5(4): e9983. DOI: 10.1371/journal.pone.0009983. ［15］ Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma［J］. Nature, 2011, 474(7353): 609-615. DOI: 10.1038/nature10166. ［16］ Dauber A, Golzio C, Guenot C, et al. SCRIB and PUF60 are primary drivers of the multisystemic phenotypes of the 8q24.3 copynumber variant［J］. Am J Hum Genet, 2013, 93(5): 798-811. DOI: 10.1016/j.ajhg.2013.09.010. ［17］ Wells C, Spaggiari E, Malan V, et al. First fetal case of the 8q24.3 contiguous genes syndrome［J］. Am J Med Genet A, 2016, 170A(1): 239-242. DOI: 10.1002/ajmg.a.37411. ［18］ Fiorentino DF, Presby M, Baer AN, et al. PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjgren′s syndrome［J］. Ann Rheum Dis, 2016, 75(6): 1145-1151. DOI: 10.1136/annrheumdis-2015-207509.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.